Autologous G-CSF-mobilized peripheral blood CD34+ cell therapy for diabetic patients with chronic nonhealing ulcer.

摘要: Recently, animal studies have demonstrated the efficacy of endothelial progenitor cell (EPC) therapy for diabetic wound healing. Based on these preclinical studies, we performed a prospective clinical trial phase I/IIa study autologous G-CSF-mobilized peripheral blood (PB) CD34(+) transplantation nonhealing foot patients. Diabetic patients with ulcers were treated 2 × 10(7) cells PB as EPC-enriched population. Safety and (wound closure vascular perfusion) evaluated 12 weeks posttherapy further followed complete recurrence. A total five enrolled. Although minor amputation recurrence seen in three out patients, no death, other serious adverse events, or major was following transplantation. Complete observed at an average 18 increased perfusion all The outcomes this indicate safety feasibility wounds.